Objective: To determine the course of thyrotropin (thyroid-stimulating hormone [TSH]) receptor antibodies (TRAbs) in children and adolescents with Graves' disease treated using antithyroid drugs (ATDs).
Main Outcomes: Twenty-two out of 23 (95.7%) patients with newly diagnosed GD, but 0/30 controls, had detectable TRAbs (22.0 ± 13.5 U/L [mean ± SD] vs. 0.9 ± 0.9 U/L; P < 0.0001). Mean TRAb levels decreased with duration of therapy, but even after 13-24 months, TRAbs had normalized in only 3/16 (18.8%) patients. The initial TRAb titer correlated significantly with severity of the initial hyperthyroidism, but did not predict the response to therapy as indicated by the dosage of ATD required to control the hyperthyroidism at 6 and 12 months.
Conclusions:
Unlike adults, most children and adolescents with Graves' disease require >2 years of ATD treatment before TRAbs are normalized. Although initial TRAb activity reflects disease severity, it does not predict the response to medical therapy. Recommendations as to treatment duration developed for adults should not be applied to the young.
COMMENT
In present study, the authors took advantage of an improved secondgeneration assay for TSH-Receptor autoantibodies (TSHR-Ab) to evaluate its sensitivity and specificity in children and adolescents with Graves' disease (GD), as well as to assess the course of TSHR-Ab in pediatric patients treated with antithyroid drugs (ATD), and finally to determine the value of initial TSHR-Ab titers for predicting the response to medical therapy. Present study is one of the largest of its kind, with a total of 146 pediatric patients investigated and followed up, among who stored sera for the retrospective analysis was available in 60% of the patients. At initial diagnosis, TSHR-Ab was positive in almost all patients (22/23). With elapsing time during ATD treatment, there was a tendency for TSHR-Ab values to decrease, but the difference from baseline did not become significant before 7-12 months. Furthermore, individual TSHR-Ab values varied widely at each time point and, even after 13-24 months with ATD, the mean TSHR-Ab titer remained elevated and became negative in only 19% (3/16) of the patients. TSHR-Ab titers in newly diagnosed GD pediatric patients were highly correlated with the initial severity of thyrotoxicosis, as reflected by total T3 concentrations. Concerning the prognostic value of TSHR-Ab determinations, the present results indicate clearly that TSHRAb values remained elevated in the majority of patients during long term ATD administration and, therefore, cannot be used as a reliable marker for predicting relapse after ATD discontinuation. Present data also re-emphasize the well-known notion that children and adolescents should receive ATD therapy for prolonged periods of time and that ATD discontinuation before two years is highly likely to be followed by a relapse of hyperthyroidism. 
